Figitumumab
Figitumumab is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer.
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.See Insulin-like growth factor 1 receptor role in cancer.The first phase III trial was suspended in December 2009 due to excess deaths but others continued.
It was to have been included in the I-SPY2 breast cancer trial.
